<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985501</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0338</org_study_id>
    <secondary_id>2019-A01346-51</secondary_id>
    <nct_id>NCT03985501</nct_id>
  </id_info>
  <brief_title>DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry</brief_title>
  <acronym>DREPAMASSE</acronym>
  <official_title>DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three methods are actually used in newborn screening for sickle cell disease (SCD) in France:
      isoelectric focusing, high performance liquid chromatography and capillary electrophoresis.
      New technologies are currently under development such as Matrix Assisted Laser Desorption
      Ionisation - Time of Flight (MALDI-TOF) and tandem mass spectrometry (MS/MS) using the SpOtOn
      Diagnostics Reagent Kit available in United Kingdom only.

      Zentech company (Liège, Belgium) is developing a package for SCD newborn screening using
      MS/MS technology. The main objective of the present study will be to compare this new
      technique with the technique actually used in the hospital center of Lille (sub-contractor
      for SCD newborn screening of Lyon) and the haemoglobin analysis to test its accuracy
      (sensitivity and specificity).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent agreement between the two techniques</measure>
    <time_frame>6 months</time_frame>
    <description>Non-inferiority (difference &lt;1%) in terms of sensitivity and specificity between the results obtained with the MS/MS method and those obtained with the technique currently used at the Lille CHU (sub-contractor for SCD newborn screening of Lyon)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1040</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Infant, Newborn, Disease</condition>
  <condition>Drepanocytosis</condition>
  <arm_group>
    <arm_group_label>newborn screening for sickle cell disease</arm_group_label>
    <description>Newborns with a targeted neonatal screening for sickle cell disease carried out at the University Hospital of Lyon</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SCD newborn screening with the MS/MS method from Zentech</intervention_name>
    <description>The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)</description>
    <arm_group_label>newborn screening for sickle cell disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants with SCD newborn screening conducted in the hospital center of Lyon
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants with SCD newborn screening conducted in the hospital center of Lyon

        Exclusion Criteria:

          -  Insufficient quantity of sampling

          -  Parents' opposition to their newborn's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>27 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Céline RENOUX, MD, PhD</last_name>
    <phone>04.27.85.65.94</phone>
    <phone_ext>+33</phone_ext>
    <email>celine.renoux@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David CHEILLAN, MD, PhD</last_name>
    <phone>04 72 12 96 88</phone>
    <phone_ext>+33</phone_ext>
    <email>david.cheillan@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupement Hospitalier Est - Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Céline RENOUX, MD, PhD</last_name>
      <phone>04.27.85.65.94</phone>
      <phone_ext>+33</phone_ext>
      <email>celine.renoux@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>David CHEILLAN, MD, PhD</last_name>
      <phone>04 72 12 96 88</phone>
      <phone_ext>+33</phone_ext>
      <email>david.cheillan@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Céline RENOUX, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muriel DORET-DION, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier CLARIS, PU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cyril HUISSOUD, PU, PH</last_name>
    </contact>
    <contact_backup>
      <last_name>Jean-Charles PICAUD, PU, PH</last_name>
    </contact_backup>
    <investigator>
      <last_name>Cyril HUISSOUD, PU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Charles PICAUD, PU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François GOLFIER, PU, PH</last_name>
    </contact>
    <investigator>
      <last_name>François GOLFIER, PU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

